Stockreport

Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact [Yahoo! Finance]

Maze Therapeutics, Inc.  (MAZE) 
PDF TheFly reported on April 14 that Truist Securities maintained its Buy rating on MAZE while reducing its price target from $68 to $64. The revision follows the company's [Read more]